Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Figure 1

Average expression of important genes and gene signatures across the intrinsic breast cancer subtypes. (a) Classical markers used to characterize breast tumors are shown for mRNA expression levels for basal markers (keratins 5 [KRT5], 14 [KRT14] and 17 [KRT17]), luminal markers (keratins 18 [KRT18] and 19 [KRT19]), ER (ESR1), PR, GATA3 and HER2 (ERBB2). Right: Box-and-whisker plot for expression of the luminal and proliferation gene signatures. (b) Markers of EMT (vimentin [VIM], Snail-1 [SNAI1], Snail-2 [SNAI2], TWIST1, TWIST2, ZEB1, ZEB2, E-cadherin [CDH1], and claudins 3 [CLDN3], 4 [CLDN4] and 7 [CLDN7]). Right: expression of stromal- and immune-related signatures [16, 17]. (c) Markers of stem cells/TICs/epithelial differentiation (CD44, CD24, EpCAM, CD10, CD49f, CD29, MUC1, THY1, and ALDH1A1). Right: Previously published stem cell-like signature [7]. Each colored square on the left side represents the relative mean transcript abundance (in log2 space) for each subtype with highest expression being red, average expression being black, and lowest expression being green. BL, basal-like; CL, claudin-low defined by SigClust [22]; H2, HER2-enriched; LA, luminal A; LB, luminal B; NBL, normal breast-like. P values shown were calculated by comparing gene expression means across all subtypes.

Back to article page